Oxford BioDynamicsLSE:OBD -21.51% Pretax Margin % is -1,088.58% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 91.58% on this metric.
The historical rank and industry rank for Oxford BioDynamics's Pretax Margin % or its related term are showing as below:
LSE:OBD'
s Pretax Margin % Range Over the Past 10 Years
Min: -4913.64 Med: -1063.88 Max: -190.1
Current: -1043.11
LSE:OBD's Pretax Margin % is ranked worse than 91.58% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs LSE:OBD: -1043.11
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Oxford BioDynamics Pretax Margin % Related Terms
Oxford BioDynamics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Oxford BioDynamics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OBD vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Oxford BioDynamics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioDynamics Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Oxford BioDynamics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioDynamics (LSE:OBD) has a Pretax Margin % of -1,088.58% as of Sep. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #185 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 91.6%.
Is Oxford BioDynamics' Pretax Margin % too high?
Oxford BioDynamics' current Pretax Margin % is -1,088.58%. Based on the distribution chart, Oxford BioDynamics ranks #185 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Oxford BioDynamics' Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #185 out of 202 companies for Pretax Margin %. This places Oxford BioDynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Oxford BioDynamics and its competitors. Oxford BioDynamics's current Pretax Margin % is -1,088.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (LSE:OBD) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.00 — trading 93.3% below its estimated fair value. The current Pretax Margin % is -1,088.58%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Oxford BioDynamics (LSE:OBD), the current Pretax Margin % is -1,088.58% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OBD has been successfully added to your 